Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SML0547

Sigma-Aldrich

Loteprednol Etabonate

≥98% (HPLC)

Sinônimo(s):

(11b,17a)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-Androsta-1,4-diene-17-carboxylic acid chloromethyl ester, CDDD 5604, HGP 1, P 5604

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C24H31ClO7
Número CAS:
Peso molecular:
466.95
Número MDL:
Código UNSPSC:
51111800
ID de substância PubChem:
NACRES:
NA.77

Nível de qualidade

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to beige

solubilidade

DMSO: 5 mg/mL, clear (warmed)

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl

InChI

1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1

chave InChI

DMKSVUSAATWOCU-HROMYWEYSA-N

Informações sobre genes

human ... NR3C1(2908)

Ações bioquímicas/fisiológicas

Loteprednol Etabonate is a "soft" steroid, typically used in topical applications for inflammatory conditions of the eye. Loteprednol Etabonate is an agonist of both glucocorticoid and mineralcorticoid receptors.
Loteprednol Etabonate is an anti-inflammatory corticosteroid (ophthalmology).
Loteprednol etabonate (LE) is a key site-active corticosteroid. It is produced by structural modifications of prednisolone-related compounds to form an inactive metabolite. Double-masked study states that loteprednol etabonate is used to treat giant papillary conjunctivitis, seasonal allergic conjunctivitis, postoperative inflammation and uveitis. LE has good ocular permeation properties.

Características e benefícios

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Edeline Lu et al.
Optometry (St. Louis, Mo.), 82(7), 413-420 (2011-05-06)
The aim of this study was to present a case of a patient who showed a significant increase in intraocular pressure (IOP) with topical administration of loteprednol etabonate 0.2%. A 29-year-old man administered 1 drop of loteprednol etabonate 0.2% (Alrex(®))
John D Sheppard et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 27(1), 23-27 (2010-12-08)
This retrospective, clinical comparative analysis describes differences in clinical signs and symptoms and medication tolerability between those patients who receive topical corticosteroids prior to initiation of topical cyclosporine 0.5% emulsion (tCSA) therapy for chronic dry eye disease (CDED) and those
Ting Liu et al.
BMC ophthalmology, 19(1), 88-88 (2019-04-10)
Small incision lenticule extraction (SMILE) and femtosecond laser-assisted in situ keratomileusis (FS-LASIK) are frequently used to treat myopia. However, little is known about the impact on recovery of these approaches in the very early postsurgical phase (within 24 h). To compare
Ting Liu et al.
Medicine, 96(30), e7409-e7409 (2017-07-27)
To evaluate the refractive outcomes of balanced salt solution infiltration during small-incision lenticule extraction (SMILE).This randomized prospective study enrolled 52 patients (104 eyes) with myopic astigmatism. Patients underwent SMILE to correct the myopic astigmatism in Daping Hospital of the Third
Brett P Bielory et al.
Acta ophthalmologica, 90(5), 399-407 (2011-11-10)
Seasonal allergic conjunctivitis (SAC) is an inflammatory response of the conjunctiva triggered by exposure to seasonal allergens. Treatment options for SAC include artificial tears, antihistamines, decongestants, mast cell stabilizers, nonsteroidal anti-inflammatory drugs, dual antihistamine/mast cell stabilizers, immunotherapy and corticosteroids. Topical

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica